Semperis Brings Award-Winning Hybrid Identity Protection Conference to Europe, Keynotes Announced
Semperis, the pioneer in identity-driven cyber resilience for enterprises, today announced that it will host the inaugural Hybrid Identity Protection (HIP) Europe Virtual Conference 2021, taking place virtually on 30 June and 1 July 2021. The first European edition of the award-winning global Hybrid Identity Protection conference series, HIP Europe will bring together leading experts working at the intersection between identity and security to provide a deep dive into the latest trends and challenges in managing hybrid and multi-cloud environments.
Keynote speakers will include Microsoft MVP Tony Redmond, aka the Exchange Godfather and author of numerous books and blogs on Microsoft Exchange and Office 365, and Microsoft Directory Services MVP and identity guru John Craddock, who has played a key role architecting identity and security solutions for industry leaders including Microsoft, the UK Government and multi-national businesses.
Organisations globally are struggling to keep up with the skyrocketing proliferation of cyberattacks — including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange — that target identity systems, especially Active Directory. HIP Europe will connect technology gurus and practitioners in an environment where they can exchange information, share war stories, and ultimately make their networks and applications more secure.
The HIP conference has earned its place as the premier educational forum for identity-centric cybersecurity leaders tasked with defending hybrid environments. First established in the US and now coming to Europe, the conference series is designed to advance the skills of IT and cybersecurity professionals through highly technical demonstrations, expert roundtables, and networking sessions. Attendees will learn best practices from local identity and access management (IAM) experts and Microsoft Most Valuable Professionals (MVPs), and connect with peers facing similar infrastructure and security challenges.
Agenda highlights
The two-day conference programme is packed with actionable insights for practitioners, from discussing the future of cloud security to identifying and recovering from directory breaches and cyber disasters. Highlights include:
- The Future of Microsoft Cloud Services. In this keynote session, Tony Redmond will look at the economics, software engineering, ecosystem and landscape of Microsoft 365 and discuss the reliability and security of Office 365.
- The Future of Identity: DIDs and VCs. This keynote by John Craddock will be an introduction to the future of identity with Decentralised Identifiers (DIDs) and Verifiable Credentials (VCs). What if users owned their identity without dependence on identity providers and only needed to prove who they are once, using that proof as often as necessary?
- Cloud Security: What’s Next? Providing a simple and unified hybrid security management engine that spans the heterogeneous space of on-premises, shared data centre and cloud is a key challenge. This session will sketch the current cloud security landscape and what challenges lie ahead for hybrid organisations.
- Deploying a Zero Trust Infrastructure. This session will demonstrate how to implement the principles of Zero Trust within a Microsoft hybrid cloud infrastructure, building on the Microsoft security stack with Azure AD, Control and Conditional Access Management features and Microsoft 365 Defender suite.
Keynote speaker and identity guru John Craddock comments: “Almost all organisations consume services from the cloud and are possibly shifting their own services to the cloud, building valuable collaborative environments providing access for their users, partners and consumers. The security boundary stretches and morphs as we create these new hybrid systems. With these elastic boundaries, identity becomes the critical component in securing our assets and managing access control. At the Hybrid Identity Protection conference, attendees can learn from industry leaders how to identify potential vulnerabilities and protect their systems for the future. A paradigm shift is around the corner with Decentralised Identity and Verifiable Credentials. My keynote will explain the benefits of this exciting new technology.”
Guido Grillenmeier, Chief Technologist at Semperis and Microsoft MVP alumnus for Directory Services, adds: “We’re excited to bring the HIP conference to Europe for the first time. It promises an amazing line-up of the world’s foremost hybrid identity experts covering today’s hottest identity security topics: the future of cloud services, cloud security and identity itself. Zero Trust is the name of the game when it comes to preventing malicious actors from stealing the keys to your kingdom – your most privileged accounts – be it on-premises or in the cloud. HIP Europe will give solid insights into how it is done right. Due to the pandemic, this will be a fully virtual experience, and it is free to attend. Security professionals can expect to discuss learnings from recent cyber incidents, experiences in recovering from attacks and how to defend modern environments against emerging threats.”
The global HIP event was established by Semperis in 2016 and has won several awards, including the 2021 Globee Business Awards – Gold Winner, Achievement of the Year in Live Events, the 2020 Cybersecurity Excellence Awards – Best Cybersecurity Conference, the Golden Bridge Business and Innovation Awards – Gold Winner, Live Event of the Year, and the 2020 IT World Awards – Bronze Winner, Security Awareness Computer-Based Training.
HIP Europe attendees can qualify for up to 12 continuing professional education (CPE) credits.
The full conference agenda is available: https://www.accelevents.com/e/HIPEurope#agenda
Registration is free: https://www.accelevents.com/e/u/checkout/HIPEurope/tickets/order
About Hybrid Identity Protection
Mobile workforces, cloud applications and digitalisation are changing every aspect of the modern enterprise. And with radical transformation come new business risks. Hybrid Identity Protection (HIP) is the premier educational forum for identity-centric practitioners. Whatever industry sector or job function, HIP strives to provide its community the insights and relationships needed to enable and protect today’s digitally driven organisations.
Twitter
https://twitter.com/HIPConf
LinkedIn
https://www.linkedin.com/company/hybrid-identity-protection-conference/
Facebook
https://www.facebook.com/HIPConf/
About Semperis
For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organisations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.
Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™. Semperis is accredited by Microsoft and recognised by Gartner.
Twitter
https://twitter.com/SemperisTech
LinkedIn
https://www.linkedin.com/company/semperis
Facebook
https://www.facebook.com/SemperisTech
YouTube
https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005112/en/
Contact information
Paula Averley
Origin Communications
E. semperis@origincomms.com
T. +44 (0)20 3814 2940
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
